Tillman Gerngross (Photo by Craig F. Walker/The Boston Globe via Getty Images)
February 15, 2023 08:35 AM EST
Startups
Deals

Till­man Gern­gross’ Am­ag­ma Ther­a­peu­tics qui­et­ly ships an­ti­bod­ies to an­oth­er biotech

Kyle LaHucik

Senior Reporter

A biotech from an­ti­body leg­end Till­man Gern­gross and stem cell leader Leonard Zon has fold­ed in­to an­oth­er com­pa­ny, merg­ing with an undis­closed biotech.

The duo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times